GLP-1之后,巨头卷向下一代减重药

第一财经
Nov 10

过去的一个周末,辉瑞和诺和诺德两大巨头之间针对减重药厂商Metsera的戏剧性竞购,最终以辉瑞胜出告终。辉瑞斥资100亿美元拿下的减重药管线中,包含了目前业内竞争相当激烈的一款胰淀素药物。  胰淀素(Amylin)药物模拟的是胰腺激素淀粉样蛋白的作用机制,它与目前已经上市的GLP-1类药物模拟肠促胰岛素的靶点机制不同,但都具有抑制食欲、减少摄食的作用。  今年早些时候,《自然综述内分泌学》(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10